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Abstract
Chaetomellic acid A is an alkyl dicarboxylic acid isolated from the fermentation of Chaetomella acutiseta.  Chaetomellic
acid A has been shown to be a potent, highly specific inhibitor of RAS farnesyl protein transferase (FPTase). The
association between RAS proteins and cancer has made chaetomellic acid A a potential chemotherapeutic agent.
Two novel chaetomellic acid A analogues have been prepared that incorporate aromatic rings in the alkyl tail. It is
anticipated that these compounds will bind more tightly to the FPTase active site than the natural product due to
intermolecular interactions between the aromatic rings in the tail and the aromatic amino acid residues that have
been shown to line the enzyme pocket.
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Introduction
Ras genes encode for RAS proteins which are
initially found in the cell cytosol.  In order to perform
their function as a molecular switch for cell growth,
RAS proteins must first become membrane bound.
This occurs through a series of post-translational
modifications (1-3). The key step in RAS membrane
association is the addition of a fifteen carbon,
farnesyl chain to the RAS protein catalyzed by the
enzyme farnesyl protein transferase (FPTase). An
intense interest in RAS proteins and FPTase has
arisen since the discovery of mutant RAS proteins
in approximately 30% of all human cancers (4). It
has been shown that mutant RAS proteins that cannot
be farnesylated, do not induce malignant trans-
formation (5). Therefore, FPTase inhibitors have
become attractive targets as potential chemo-
therapeutic agents.
Since its isolation in 1993 (6), chaetomellic acid
A [1] has been synthesized via multiple routes (7-
15) and shown to be a potent and highly specific
inhibitor of FPTase (IC50 human FPTase = 55 nM).
Chaetomellic acid A is a competitive inhibitor of
FPTase, mimicking the enzymes natural substrate,
farnesyl pyrophosphate (FPP). While most research
in the area of FPP mimetics has focused on
modifications to the biologically labile diphosphate
“head” (16-21), manipulation of the hydrophobic
farnesyl “tail” has also been shown to influence
binding to the enzyme active site. For example, the
presence of a benzoylbenzyl group in the “tail” of
an FPP mimetic gives a slight increase (1.5-fold) in
the binding affinity for FPTase (22). This data along
with the publication of a crystal structure of FPTase
(23,24), revealing a hydrophobic pocket lined with
ten aromatic amino acid residues that accepts the
terpenoid chain, has led to the hypothesis that the
addition of aromatic rings into the hydrophobic “tail”
will enhance the binding affinity of FPP analogues.
To prove this hypothesis, two analogues of chaeto-
mellic acid A have been prepared (Figure 1).  One
analogue incorporates one aromatic ring in the alkyl
“tail” [2] and the other analogue incorporates two
aromatic rings [3]. Molecular modeling studies show
that both of these analogues, 2 and 3, are similar in
length to the natural product [1], 22.019 Å, 21.86 Å,
and 22.031 Å respectively (25). It is anticipated that
these compounds will be better FPTase inhibitors
than chaetomellic acid A, thus illuminating the
Figure 1
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Scheme 1.
importance of nonbonding interactions in enzymatic
recognition of the hydrophobic “tail”.
Experimental
Tetrahydrofuran (THF) was distilled from sodium/
benzophenone immediately prior to use, while
dichloromethane was freshly distilled from calcium
hydride. All reactions in these solvents were
conducted in oven-dried glassware under a positive
pressure of nitrogen. Column chromatography was
performed on 230-400 mesh silica gel. NMR spectra
(1H NMR at 300 MHz and 13C NMR at 75 MHz)
were recorded on a JEOL 300 MHz NMR
spectrometer (JEOL-USA, Inc. Peabody, MA) with
CDCl3 solvent. High-resolution mass spectra were
obtained on a Bruker BioTOF II mass spectrometer
(Bruker Daltonics Inc. Billerica, MA) at the
University of Minnesota Mass Spectrometry Service
Laboratory. All starting chemicals were purchased
from Aldrich (Milwaukee, WI) and used as received.
11-phenyl-10-undecen-1-ol [5]
A mixture of tetrahydropyran 4 (26) (3.42 g, 10.7
mmoles) and triphenylphosphine (3.33 g, 12.7
mmoles) was placed in a flame-dried 50 mL round-
bottom flask fitted with a reflux condenser and stirred
at 120oC for 1 hour. Upon generation of the
phosphonium salt, the reaction mixture was cooled
to 75oC and 30 mL of THF was added through
the reflux condenser. The resulting solution
was vigorously stirred and allowed to cool
to room temperature. Once at room
temperature, the solution was treated with n-
BuLi (5.4 mL of a 2.5 M solution in hexanes,
13.5 mmol) to generate the ylide (red color).
The mixture was allowed to stir for 5 minutes
and then benzaldehyde was added dropwise
(1.3 mL, 12.8 mmol). The Wittig reaction was
allowed to stir for 1 hour and then
subsequently quenched with 1 M HCl and
extracted with dichloromethane. The
combined organic extracts were dried over
sodium sulfate and concentrated in vacuo.
The crude oil obtained in this manner was
placed in anhydrous methanol (20 mL) and
treated with p-toluenesulfonic acid (246 mg,
1.29 mmol). The reaction mixture was
allowed to stir overnight (15 hours) and then
concentrated directly under vacuum to
provide a yellow oil. Final purification by column
chroma-tography (60:40 hexanes:ethyl acetate)
afforded 11-phenyl-10-undecen-1-ol [5] as a 1.7:1.0
mixture of cis:trans isomers (1.93 g, 74%): 1H NMR
δ 7.39-7.14 (m, 5H), 6.41 (d, 1H, J = 11.8 Hz, cis),
6.38 (d, 1H, J = 15.7 Hz, trans), 6.22 (dt, 1H, J =
15.9, 6.6 Hz, trans), 5.66 (dt, 1H, J = 11.5, 7.4 Hz,
cis), 3.63 (t, 2H, J = 6.6 Hz), 2.32 (m, 2H, cis), 2.20
(m, 2H, trans), 1.61-1.21 (m, 14H).
11-phenyl-1-undecanol [6]
A solution of alkene 5 (53 mg, 0.22 mmol) in
anhydrous methanol (2 mL) was placed in a 5 mL
round-bottom flask and treated with 5% palladium
on carbon (43 mg, 0.020 mmol). The flask was placed
under a hydrogen atmosphere by using a hydrogen
balloon and allowed to stir for 3 hours. The reaction
mixture was filtered through celite and silica gel
(diethyl ether rinse) and concentrated in vacuo to
afford 11-phenyl-1-undecanol [6] as a clear oil which
solidifies to a white solid when placed in the freezer
(50 mg, 94%): 1H NMR  δ 7.30-7.14 (m, 5H), 3.64
(t, 2H, J = 6.6 Hz), 2.60 (t, 2H, J = 7.7 Hz), 1.58 (m,
2H), 1.44 (br s, 1H), 1.37-1.22 (m, 16H); 13C NMR
δ 143.0, 128.5 (2C), 128.3 (2C), 125.6, 63.2, 36.1,
32.9, 31.6, 29.7-29.4 (6C), 25.8; HRMS calcd for
C17H28O (M + Na)+ 271.397, found 271.2025.
11-phenyl-1-undecanal [7]
Alcohol 6 (720 mg, 2.90 mmol), pyridinium
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Scheme 2
dichromate (PDC) (1.64 g, 4.35 mmol), and
dichloromethane (25 mL) were placed in a flame-
dried 50 mL round-bottom flask and allowed to stir
overnight (17 hours). The resulting suspension was
diluted with ether and filtered through a thin layer
of celite and silica gel. The filtrate was concentrated
under vacuum and purified by column chroma-
tography (80:20 hexanes:ethyl acetate) to afford
aldehyde 7 (690 mg, 97%): 1H NMR  δ 9.76 (t, 1H,
J = 1.6 Hz), 7.32-7.12 (m, 5H), 2.60 (t, 2H, J = 7.4
Hz), 2.41 (dt, 2H, J = 1.9, 7.3 Hz), 1.67-1.54 (m,
2H), 1.28 (br s, 14H); 13C NMR  δ 203.1, 143.0,
128.5 (2C), 128.3 (2C), 125.6, 44.0, 36.1, 31.6, 29.6-
29.2 (6C), 22.2.
N-p-tolylsuccinimide [9]
A mixture of aldehyde 7 (210 mg, 0.854 mmol),
triphenylphosphine (235 mg, 0.896 mmol), and
citraconimide 8 (27) (180 mg, 0.896 mmol) was
placed in glacial acetic acid (5 mL) and heated to
reflux with stirring overnight (17 hours). The acetic
acid was removed under reduced pressure and the
resulting oil was purified by column chromatography
(85:15 hexanes:ethyl acetate). A 6.1:1.0 mixture of
E:Z isomers of N-p-tolylsuccinimide 9 was obtained
(210 mg, 57%): 1H NMR  δ 7.33-7.16 (m, 9H), 6.94
(dt, 1H, J = 2.2, 8.0 Hz, E), 6.24 (dt, 1H, J = 1.9, 7.7
Hz, Z), 3.51-3.42 (m, 1H, E), 3.42-3.32 (m, 1H, Z),
2.93-2.79 (m, 2H, Z), 2.64 (t, 2H, J = 7.4 Hz), 2.41
(s, 3H), 2.40-2.21 (m, 2H, E), 1.72-1.58 (m, 2H),
1.54 (d, 3H, J = 7.4 Hz, E), 1.49 (d, 3H, J = 7.4 Hz,
Z), 1.33 (br s, 14H).
Anhydride [10]
Sodium metal (130 mg, 5.65 mmol) and
anhydrous methanol (10 mL) were mixed
together to generate a 0.565 M solution of
sodium methoxide in situ.  Succinimide 9 (170
mg, 0.394 mmol) was placed in a 10 mL round-
bottom flask and subsequently treated with the
freshly prepared 0.565 M sodium methoxide
solution (5.0 mL, 2.8 mmol). The resulting
mixture was heated at reflux for 2 hours and then
the methanol solvent was removed under
vacuum. The resulting residue was acidified with
3 M HCl, extracted with diethyl ether, and
concentrated.  The crude yellow oil was purified
by column chromatography (80:20
hexanes:ethyl acetate) to afford pure anhydride
10 (30 mg, 22%): 1H NMR  δ 7.31-7.13 (m, 5H),
2.60 (t, 2H, J = 7.4 Hz), 2.45 (t, 2H, J = 7.4 Hz),
2.06 (s, 3H), 1.67-1.51 (m, 2H), 1.37-1.23 (m,
16H); 13C NMR  δ 166.4, 166.0, 144.9, 143.0,
140.5, 128.5 (2C), 128.3 (2C), 125.6, 36.1, 31.6,
29.6, 29.6, 29.6, 29.5, 29.5, 29.4, 29.2, 27.7, 24.5,
9.6; HRMS calcd for C22H30O3 (M + Na)+ 365.466,
found 365.2096.
Alkenol [13]
In a similar procedure as described above for 11-
phenyl-10-undecen-1-ol [5], THP ether 11 (26) (1.58
g, 5.96 mmol) and triphenyl phosphine (1.87 g, 7.13
mmol) were stirred for 1 hour at 120oC. The
phosphonium salt was diluted with THF (20 mL)
and treated with n-BuLi (2.9 mL of a 2.5 M solution
in hexanes, 7.2 mmol). Generation of the ylide was
followed by the addition of a solution of
3-(phenylmethyl)benzaldehyde 12 (28) (1.3 g, 6.6
mmol) in THF (10 mL) via cannula. The reaction
was allowed to stir for 2 hours and worked-up as
described above for compound 5. The crude product
was diluted in anhydrous methanol (100 mL) and
treated with p-toluenesulfonic acid (1.15 g, 6.05
mmol). Purification by column chromatography
(65:35 hexanes:ethyl acetate) provided pure alkenol
13 as a 2.6:1.0 mixture of cis:trans isomers (1.11 g,
67%): 1H NMR  δ 7.38-7.03 (m, 9H), 6.42 (d, 1H,
J = 11.8 Hz, cis), 6.39 (d, 1H, J = 15.7 Hz, trans),
6.23 (dt, 1H, J = 15.7, 6.6 Hz, trans), 5.67 (dt, 1H,
J = 11.5, 7.4 Hz, cis), 4.01 (s, 2H, cis), 4.00 (s, 2H,
trans), 3.66 (t, 2H, J = 6.6 Hz, trans), 3.63 (t, 2H,
J = 6.6 Hz, cis), 2.33 (m, 2H, cis), 2.24 (m, 2H, trans),
1.68-1.32 (m, 6H).
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3-(phenylmethyl)benzeneheptanol [14]
Alkenol 13 (110 mg, 0.393 mmol), 5% palladium
on carbon (120 mg, 0.0569 mmol), and methanol (4
mL) were stirred under a hydrogen atmosphere in a
similar procedure as described for 11-phenyl-1-
undecanol [6] above. Standard work-up provided
alcohol 14 as a clear oil (420 mg, 83%):  1H NMR  δ
7.37-7.18 (m, 6H), 7.09-7.01 (m, 3H), 4.00 (s, 2H),
3.65 (t, 2H, J = 6.6 Hz), 2.61 (t, 2H, J = 7.4 Hz),
1.80 (br s, 1H), 1.70-1.53 (m, 2H), 1.38 (br s, 8H);
13C NMR  δ 143.1, 141.4, 141.1, 129.2, 129.1 (2C),
128.5 (2C), 128.5, 126.4, 126.3, 126.1, 63.1, 42.1,
36.0, 32.9, 31.5, 29.4 (2C), 25.7; HRMS calcd for
C20H26O (M + Na)+ 305.414, found 305.1875.
3-(phenylmethyl)benzeneheptanal [15]
Following the procedure described above for the
preparation of aldehyde 7, alcohol 14 (110 mg, 0.390
mmol), PDC (220 mg, 0.585 mmol), and dichloro-
methane (5 mL) were allowed to stir for 19 hours.
Upon standard work-up and purification by column
chromatography (80:20 ethyl acetate:hexanes), pure
aldehyde 15 was isolated as a clear oil (100 mg,
92%): 1H NMR  δ 9.80 (t, 1H, J = 1.7 Hz), 7.41-
7.25 (m, 6H), 7.15-7.08 (m, 3H), 4.06 (s, 2H), 2.67
(t, 2H, J = 7.4 Hz), 2.45 (dt, 2H, J = 1.7, 7.3 Hz),
1.76-1.64 (m, 4H), 1.47-1.39 (m, 4H); 13C NMR  δ
202.8, 143.0, 141.5, 141.2, 129.3, 129.1 (2C), 128.6
(2C), 128.6, 126.5, 126.3, 126.2, 44.0, 42.1, 36.0,
31.4, 29.2 (2C), 22.2.
N-p-tolylsuccinimide [16]
Following the same procedure used to prepare N-
p-tolylsuccinimide 9, a mixture of aldehyde 15 (270
mg, 0.964 mmol), triphenylphosphine (265 mg, 1.01
mmol), and citraconimide 8 (27) (203 mg, 1.01
mmol) was placed in glacial acetic acid (8 mL) and
heated to reflux with stirring overnight (21 hours).
The acetic acid was removed under reduced pressure.
The resulting oil was purified by column chroma-
tography (90:10 hexanes:ethyl acetate) and a 6.4:1.0
mixture of E:Z isomers of N-p-tolylsuccinimide 16
was obtained (181 mg, 41%): 1H NMR  δ 7.38-7.23
(m, 10H), 7.12-7.06 (m, 3H), 6.96 (dt, 1H, J = 2.2,
8.0 Hz, E), 6.25 (dt, 1H, J = 1.9, 8.0 Hz, Z), 4.03 (s,
2H, E), 4.02 (s, 2H, Z), 3.52-3.42 (m, 1H, E), 3.44-
3.34 (m, 1H, Z), 2.97-2.83 (m, 2H, Z), 2.65 (t, 2H,
J = 7.4 Hz), 2.43 (s, 3H, E), 2.42 (s, 3H, Z), 2.40-
2.24 (m, 2H, E), 1.75-1.61 (m, 2H), 1.56 (d, 3H, J =
7.4 Hz, E), 1.51 (d, 3H, J = 7.4 Hz, Z), 1.49-1.37 (m,
6H).
Anhydride [17]
Following the same procedure used to synthesize
anhydride 10, anhydride 17 was prepared from
succinimide 16. 15 mL of a freshly prepared 0.87 M
sodium methoxide solution was added to succinimide
16 (181 mg, 0.389 mmol) and the mixture was heated
at reflux for 3 hours. Removal of methanol under
vacuum, acidification with 3 M HCl, and diethyl
ether extraction provided a yellow oil which was
purified by column chromatography (90:10
hexanes:ethyl acetate) to afford pure anhydride 17
(60 mg, 41%): 1H NMR  δ 7.33-7.15 (m, 6H), 7.05-
6.98 (m, 3H), 3.97 (s, 2H), 2.57 (t, 2H, J = 7.7 Hz),
2.44 (t, 2H, J = 7.4 Hz), 2.06 (s, 3H), 1.66-1.50 (m,
4H), 1.38-1.28 (m, 6H); 13C NMR  δ 166.3, 166.0,
144.8, 142.9, 141.4, 141.1, 140.5, 129.2, 129.0 (2C),
128.5 (2C), 128.4, 126.4, 126.2, 126.1, 42.0, 35.9,
31.4, 29.4, 29.2, 29.2, 27.6, 24.5, 9.6; HRMS calcd
for C25H28O3 (M + Na)+ 399.483, found 399.1915.
Results and Discussion
The preparation of anhydrides 10 (Scheme 1) and
17 (Scheme 2) were accomplished using similar
reaction sequences.  The synthesis of anhydride 10
began with 10-bromo-1-(tetrahydropyranyloxy)
decane 4, which was prepared in two known steps
from commercially available 1,10-decanediol (26).
Bromide 4 was subsequently converted to a phos-
phorus ylide upon treatment with triphenylphosphine
followed by n-butyllithium. Addition of benz-
aldehyde to the ylide provided the desired Wittig
product in high yield. The coupling proceeded
smoothly except for one problem. Under the Wittig
reaction conditions, some cleavage of the tetra-
hydropyranyl ether protecting group was observed.
The resulting Wittig product was therefore not
purified, but carried directly into the deprotection
step. Treatment with p-toluenesulfonic acid
converted all of the Wittig product to alkenol 5,
providing a 74% yield over the two steps.  Alkenol 5
was isolated as a 1.7:1.0 mixture of cis:trans isomers
(29) that was converted to a single compound,
alcohol 6, upon hydrogenation over palladium on
carbon. With alcohol 6 in hand, a procedure
previously developed to convert tetradecanol to
chaetomellic anhydride A was employed to prepare
anhydride 10 (7). Alcohol 6 was transformed to
aldehyde 7 using a chromium oxidation. The
aldehyde was condensed with known citraconimide
8 (27) under acidic conditions to yield
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N-p-tolylsuccinimide 9 as a 6.1:1.0 mixture of E and
Z isomers (29). Treatment of the mixture with sodium
methoxide in methanol followed by acidification
resulted in the preparation of anhydride 10 in
moderate yield.
Anhydride 17 was prepared using the same
sequence as described above for anhydride 10. There
are only two differences in the synthetic sequences.
First, anhydride 17 was synthesized from a shorter
bromotetrahydropyranyl ether. Commerically
available 1,6-hexanediol was used instead of 1,10-
decanediol as a starting material to prepare 6-bromo-
1-(tetrahydropyranyloxy)hexane 11 (26). Second, the
Wittig reagent prepared from bromide 11 was
coupled with 3-(phenylmethyl)benzaldehyde (12)
instead of benzaldehyde. Aldehyde 12 was prepared
in three steps from commercially available 3-
bromobenzaldehyde (28). The Wittig product was
deprotected and hydrogenated to alcohol 14 as
described above. Once obtained, alcohol 14 was
converted to anhydride 17 following the three step
protocol established in synthesizing anhydride 10
from alcohol 6.
Conclusion
In summary, two chaetomellic acid A analogues
have been prepared, analogue 10, incorporating one
aromatic ring, and analogue 17, incorporating two
aromatic rings. Both of these compounds were
prepared in eight linear steps with overall yields of
7.5% and 7.6% respectively. Although synthesized
in the anhydride form, for bioassaying purposes,
compounds 10 and 17 are chaetomellic acid A
analogues. It has been shown that under typical assay
conditions (pH 7.5), chaetomellic anhydride A opens
up to the biologically active dicarboxylate form of
chaetomellic acid A with no loss of FPTase activity
(6). The same results should hold true for chaeto-
mellic anhydride analogues 10 and 17. Under basic
bioassay conditions, they will be converted to the
diacid  salts of compounds 2 and 3 (Figure 1) in situ.
In this manner, compounds 10 and 17 will serve as
useful probes to investigate the importance of non-
bonding interactions in enzymatic recognition of the
hydrophobic “tail”.
Acknowledgment
Financial support from a University of Minnesota
RSEC grant is gratefully acknowledged.
References
(1). C.J. Marshall. Science, 1993, 259, 1865-1866.
(2). M. Nigam, C.-M. Seong, Y. Qian, A.D. Hamilton;S.M.
Sebti. J. Biol. Chem., 1993, 268, 20695-20698.
(3). J.B. Gibbs, A. Oliff, and N.E. Kohl. Cell, 1994, 77,
175-178.
(4). M. Barbacid. Annu. Rev. Biochem., 1987, 56, 779-
827.
(5). A.M. Garcia, C. Rowell, K. Ackermann, J.J.
Kowalczyk; M.D. Lewis. J. Biol. Chem., 1993, 268,
18415-18418.
(6). S.B. Singh, D.L. Zink, J.M. Liesch, M.A. Goetz, R.G.
Jenkins, M. Nallin-Omstead, K.C. Silverman, G.F.
Bills, R.T. Mosley, J.B. Gibbs, G. Albers-Schonberg;
R.B. Lingham. Tetrahedron, 1993, 49, 5917-5926.
(7). S.B. Desai; N.P. Argade. J. Org. Chem., 1997, 62,
4862-4863.
(8). N.P. Argade; R.H. Naik. Bioorg. Med. Chem., 1996,
4, 881-883.
(9). A.M. Deshpande, A.A. Natu; N.P. Argade. J. Org.
Chem., 1998, 63, 9557-9558.
(10). A. Kar; N.P. Argade.  J. Org. Chem., 2002, 67, 7131-
7134.
(11). S.B. Singh. Tetrahedron Lett., 1993, 34, 6521-6524.
(12). E.S. Ratemi, J.M. Dolence, C.D. Poulter; J.C.
Vederas. J. Org. Chem., 1996, 61, 6296-6301.
(13). M.J. Kates; J.H. Schauble. J. Org. Chem., 1996,
61, 4164-4167.
(14). R.M. Slade; B.P. Branchaud. J. Org. Chem., 1998,
63, 3544-3549.
(15). S. Poigny, M. Guyot; M. Samadi. J. Chem. Soc.
Perkin Trans. 1, 1997, 2175-2177.
(16). D.V. Patel, R.J. Schmidt, S.A. Biller, E.M. Gordon,
S.S. Robinson; V. Manne. J. Med.Chem., 1995, 38,
2906-2921.
(17). M.S. Kang, D.M. Stemerick, J.H. Zwolshen, B.S.
Harry, P.S. Sunkara; B.L. Harrison. Biochem. Biophys.
Res. Commun., 1995, 217, 245-249.
(18). D.R. Mangin, S.A. Biller, J.K. Dickson, Jr., J.V.
Logan, R.M. Lawrence, Y. Chen, R.B. Sulsky, C.P.
Ciosek, Jr., T.W. Harrity, K.G. Holibois, L.K.
Kunselman, L.C. Rich; D.A. Slusarchyk. J. Med.
Chem., 1995, 38, 2596-2605.
(19). D.L. Pompliano, E. Rands, M.D. Schaber, S.D.
Mosser, N.J. Anthony; J.B. Gibbs. Biochemistry, 1992,
31, 3800-3807.
(20). A.R.P.M. Valentijn, O. van den Berg, G.A. van der
Marel, L.H. Cohen; J.H. van Boom. Tetrahedron, 1995,
Journal of Undergraduate Chemistry Research, 2005, 1, 122
51, 2099-2108.
(21). S.A. Holstein, D.M. Cermak, D.F. Wiemer, K. Lewis;
R.J. Hohl. Bioorganic & Medicinal Chemistry, 1998,
6, 687-694.
(22). I. Gaon, T.C. Turek; M.D. Distefano. Tetrahedron
Lett., 1996, 37, 8833-8836.
(23). H. Park, S.R. Boduluri, J.F. Moomaw, P.J. Casey;
L.S. Beese. Science, 1997, 275, 1800-1804.
(24). S.B. Long, P.J. Casey, and L.S. Beese. Biochemis-
try, 1998, 37, 9612-9618.
(25). Molecular modeling studies (semi-emperical PM3
optimization) were performed using Spartan 2002
V1.0.3 software.
(26). 10-bromo-1-(tetrahydropyranyloxy)decane 4 and 6-
bromo-1-(tetrahydropyranyloxy)hexane 11 were both
prepared in two steps: Monobromination of 1,10-
decanediol and 1,6-hexanediol respectively (J.M.
Chong, M.A. Heuft; P. Rabbat. J. Org. Chem., 2000,
65, 5837-5838) followed by THP ether protection (L.
Thijs and B. Zwanenburg. Tetrahedron, 2004, 60, 5237-
5252).
(27). Citraconimide 8 was prepared in one step from
citraconic anhydride and p-toluidine (D.Choi, S.
Huang, M. Huang, T.S. Barnard, R.D. Adams, J.M.
Seminario; J.M. Tour. J. Org. Chem., 1998, 63, 2646-
2655).
(28). 3-(Phenylmethyl)benzaldehyde 12 was prepared in
three steps from 3-bromobenzaldehyde (K. Matsuda,
N. Nakamura, K. Takahashi, K. Inoue, N. Koga, and
H. Iwamura. J. Am. Chem. Soc., 1995, 117, 5550-5560.
(29). The ratio of E and Z isomers was determined by 1H
NMR integration.
